Compare AQMS & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AQMS | HCWB |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 14.8M |
| IPO Year | 2015 | 2021 |
| Metric | AQMS | HCWB |
|---|---|---|
| Price | $2.76 | $4.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $12.00 | ★ $35.00 |
| AVG Volume (30 Days) | 99.8K | ★ 601.3K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | $2,100,000.00 | ★ $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $600.00 | N/A |
| P/E Ratio | ★ N/A | $12.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.25 |
| 52 Week High | $39.37 | $7.35 |
| Indicator | AQMS | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 32.46 | 71.80 |
| Support Level | $2.51 | $0.59 |
| Resistance Level | $4.36 | $4.88 |
| Average True Range (ATR) | 0.19 | 0.31 |
| MACD | 0.01 | 0.34 |
| Stochastic Oscillator | 5.33 | 74.53 |
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting, and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.